Skip to main content

Advertisement

Table 1 Characteristics of patients in this substudy according to the treatment

From: Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

Characteristic FEC (N= 546) FEC-D (N= 553) P-value
Age    0.794
   <50 years 261 (47.8%) 260 (47.0%)  
   ≥50 years 285 (51.2%) 293 (53.0%)  
Menopausal status    0.770
   Premenopausal 332 (61.8%) 331 (61.0%)  
   Postmenopausal 214 (38.2%) 222 (39.0%)  
Surgery    
   Breast conservation 313 (57.3%) 342 (61.8%) 0.127
   Modified mastectomy 233 (42.7%) 211 (38.2%)  
Pathological tumor size (pT)    
   <2 cm 163 (32.2%) 200 (39.9%) 0.039
   2 ≤pT <-5 cm 306 (60.5%) 269 (53.7%)  
   ≥5 cm 37 (7.3%) 32 (6.4%)  
SBR Grade    
   I 52 (9.6%) 67 (12.2%) 0.288
   II 231 (42.6%) 238 (43.2%)  
   III 237 (43.7%) 217 (39.4%)  
   Not gradable 22 (4.1%) 29 (5.3%)  
Positive lymph nodes 329 (60.3%) 342 (61.8%) 0.589
   1 to 3 217 (39.7%) 211 (38.2%)  
   ≥4    
Hormone receptors    
   Positive (ER and/or PR) 414 (78.0%) 419 (78.0%) 0.981
   Negative (ER and PR) 117 (22.0%) 118 (22.0%)  
Estrogen receptor    
   Positive 394 (74.2%) 391 (72.8%) 0.607
   Negative 137 (25.8%) 146 (27.2%)  
Progesterone receptor    
   Positive 276 (52.0%) 305 (56.7%) 0.122
   Negative 255 (48.0%) 233 (43.3%)  
HER2    
   Positive 93 (17.1%) 82 (15.0%) 0.337
   Negative 451 (82.9%) 466 (85.0%)  
DFS, event    
   Yes 150 (27%) 118 (21%) 0.021
   No 396 (73%) 435 (79%)